8月10日，荣昌生物盘中上涨3.88%，报90.0港元，成交额1.22亿港元。
消息面上，公司此前披露半年度业绩预告，预计上半年营收约58.5亿元，同比增长约433%；归母净利润约47亿元，较上年同期净亏损4.5亿元实现扭亏为盈。业绩大幅增长主要受益于核心产品泰它西普、维迪西妥单抗国内销售持续放量，以及与艾伯维就RC148签署独家授权许可协议带来的技术授权收入（首付款6.5亿美元）大幅增加。此外，新版国家基本药物目录近期发布，公司关键品种有望迎来进一步放量机会，生物科技板块整体走强形成联动效应。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.